Moleculin Biotech (NASDAQ:MBRX) Cut to Strong Sell at Wall Street Zen

Wall Street Zen lowered shares of Moleculin Biotech (NASDAQ:MBRX) from a sell rating to a strong sell rating in a report published on Saturday,Wall Street Zen reports.

A number of other brokerages have also weighed in on MBRX. Weiss Ratings restated a “sell (e+)” rating on shares of Moleculin Biotech in a research note on Thursday, October 15th. HC Wainwright reduced their price target on shares of Moleculin Biotech to $60.00 and set a “buy” rating on the stock in a research report on Friday, August 28th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $60.00.

Moleculin Biotech Stock Down 0.5%

MBRX stock opened at $8.66 on Friday. The business has a fifty day moving average price of $10.37 and a 200 day moving average price of $38.40. Moleculin Biotech has a fifty-two week low of $3.23 and a fifty-two week high of $253.05.

Moleculin Biotech (NASDAQ:MBRX) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($28.00) EPS for the quarter, topping analysts’ consensus estimates of ($31.00) by $3.00. Equities analysts anticipate that Moleculin Biotech will post -47.40 EPS for the current year.

About Moleculin Biotech

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on developing treatments for cancers and other serious diseases. The company uses its proprietary technology platforms to design drug candidates intended to address treatment resistance, improve drug delivery, and target biological pathways involved in disease progression.

Moleculin’s lead program is Annamycin, a liposomal formulation of the anthracycline doxorubicin being investigated for acute myeloid leukemia and soft-tissue sarcoma.